memantine has been researched along with Parkinsonian Disorders in 5 studies
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Silibinin administration restored these mitochondrial disorders, as expected for the protection against MPTP injury." | 1.62 | Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus. ( Fu, J; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, W; Liu, X; Mizuno, K; Song, S; Wang, C, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Wang, C | 1 |
| Liu, W | 1 |
| Song, S | 1 |
| Fu, J | 1 |
| Hayashi, T | 1 |
| Mizuno, K | 1 |
| Hattori, S | 1 |
| Fujisaki, H | 1 |
| Ikejima, T | 1 |
| Lee, JE | 1 |
| Kim, HN | 1 |
| Kim, DY | 1 |
| Shin, YJ | 1 |
| Shin, JY | 1 |
| Lee, PH | 1 |
| Zhu, G | 1 |
| Li, J | 1 |
| He, L | 1 |
| Wang, X | 1 |
| Hong, X | 1 |
| Hanağasi, HA | 1 |
| Kaptanoglu, G | 1 |
| Sahin, HA | 1 |
| Emre, M | 1 |
| Fredriksson, A | 1 |
| Danysz, W | 1 |
| Quack, G | 1 |
| Archer, T | 1 |
5 other studies available for memantine and Parkinsonian Disorders
| Article | Year |
|---|---|
Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; alpha-Synuclein; Animals; Apopto | 2021 |
Memantine exerts neuroprotective effects by modulating α-synuclein transmission in a parkinsonian model.
Topics: alpha-Synuclein; Animals; Cell Line; Humans; Memantine; Mice, Inbred C57BL; Neurons; Neuroprotective | 2021 |
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Ag | 2015 |
The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2000 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine | 2001 |